Shared lipid synthesis in neutrophils and platelets may limit tissue damage
Suppressing the prostaglandin E2 receptor EP2 may preserve recovery through lipoxin synthesis by neutrophils and platelets despite blocked neutrophil engulfment. No dependence on platelet 12-lipoxygenase after its confirmed inactivation would reject this mechanism.
Stage of verification
- Hypothesis published2026-09-30
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.

Receptor or channel
EP2 receptor
A receptor whose activity can be suppressed
Where this hypothesis actsResident macrophage environment and coordinated lipid synthesis by neutrophils and platelets
Hypotheses on this target 5
Lower level
Higher level
Blockade5
Agonism
Desensitisation
Function restoration
Function preservation

What is proposed
Blockade
Suppress EP2 activity
With whatNot stated in the record
HowNot stated in the record
Possible result
Possible reduction in SPV_3 and new damage across several tissues despite blocked neutrophil engulfment
From the recordПодавление EP2 предположительно меняет среду резидентных макрофагов

Enzyme
12-lipoxygenase
An enzyme that participates in converting lipid precursors into synthesis products
Where this hypothesis actsPlatelets processing a neutrophil-derived precursor into lipoxins during EP2 suppression
Hypotheses on this target 1
Inhibition1
Activation
Lower level
Higher level
Replacement
Protection from degradation
Cofactor removal
Synthesis suppression
Function preservation

What is proposed
Inhibition
Disable 12-lipoxygenase selectively in platelets
With whatNot stated in the record
HowPlatelet-specific inactivation while preserving neutrophil numbers, vesicular CD55 activity and itaconate flux
Possible result
Expected loss of the benefit of EP2 suppression if platelet-dependent lipid synthesis is causal
From the recordТромбоцит-специфическое выключение 12-липоксигеназы устраняет этот эффект

Immune response
Efferocytosis
The engulfment and clearance of apoptotic cells by phagocytes
Where this hypothesis actsNeutrophil engulfment during EP2 suppression
Hypotheses on this target 8
Inhibition5
Activation2
Function preservation
Clearance restoration1
Immunosuppression
Feedback restoration
Rhythm restoration

What is proposed
Inhibition
Block neutrophil engulfment
With whatNot stated in the record
HowNot stated in the record
Possible result
Expected persistence of EP2 suppression benefits with increased lipoxin formation despite blocked engulfment
From the recordПольза подавления EP2 сохраняется при блокаде поглощения нейтрофилов
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Immune cells that remain in tissue might help stop further damage rather than simply prolong it. The unexpected move is to propose that retained neutrophils supply material that platelets convert into protective chemicals, so benefit could persist even when other cells cannot swallow the neutrophils. This is a hypothesis generated by the pipeline, not a measured explanation of protection across tissues.
- EP2 suppression is proposed to change the local environment of tissue-resident macrophages.
- The changed environment is proposed to shift the products made jointly by neutrophils and platelets.
- Neutrophils retained because engulfment is blocked are proposed to remain chemical suppliers rather than becoming unavailable through removal.
- Platelet 12-lipoxygenase converts the supplied neutrophil intermediate into lipoxins.
- Restored production through this shared pathway is predicted to shorten inflammation and limit new damage in several tissues.
Two workshops share a production line: the first makes an unfinished part, and the second turns it into a useful product. Keeping the first workshop open helps only if the second workshop can still complete the job.
Where the picture breaks: Retained neutrophils can also contribute to damage, and their presence does not establish that material is reaching platelets or becoming lipoxins. The amount passing through the proposed pathway has to be measured.
- Master questionstep 01 of 04
Processes involved in aging may reinforce one another, making a shared cause a possible target for improving several body systems at once.
Rests on: The goal is to generate life-extension ideas that act on a cause shared by several aging processes.
AssumptionThe search assumes that a shared causal target can be altered in a way that benefits several systems. The goal supplies this possibility, not evidence that such a target exists.
- Goal pillarstep 02 of 04
Recovery should remain possible instead of giving way to a persistent damaged state.
Rests on: The master question seeks a common cause through which several systems could benefit together.
AssumptionThe narrowing assumes that persistence of a damaged state is a useful shared target. The master question does not specifically establish that choice.
- Gap questionstep 03 of 04
Protection from blocking EP2 might persist when restoration of neutrophil removal is selectively prevented. Such persistence would challenge the claim that removing these cells is necessary for the shared benefit.S7
Rests on: The supplied abstract from Science in 2026 reports that reducing EP2 signaling in tissue-resident macrophages, immune cells that live in tissues and engulf other cells, protected several functions in aged mice. It does not examine benefit during blocked neutrophil engulfment or establish the proposed shared chemical pathway.
Supported by literature - Hypothesisstep 04 of 04
Blocking EP2 is proposed to change the surroundings of tissue-resident macrophages and shift chemical production shared by neutrophils and platelets. Platelet 12-lipoxygenase, an enzyme that converts certain fat-derived molecules, would turn a neutrophil intermediate into lipoxins, fat-derived signals proposed here to help inflammation end. Neutrophils retained during blocked engulfment would continue supplying this pathway, shortening the time inflammation takes to resolve and limiting new damage across tissues.S1
Rests on: The preceding question leaves open how protection could survive blocked cell removal. The Journal of Clinical Investigation study from 1990 supports conversion of a neutrophil-derived intermediate into lipoxins by platelet 12-lipoxygenase in laboratory preparations from human cells; it does not establish the effects of EP2 suppression, retained neutrophils, or protection across tissues.
Supported by literature
What is carried, and what is not. S1 directly supports one central chemical conversion in human-cell laboratory preparations, without establishing its operation after EP2 suppression; S7 reports protection across several functions in aged mice, without testing the proposed conversion or blocked neutrophil engulfment. These support separate parts of the argument, but no supplied source establishes the sequence from EP2 suppression through continued shared lipoxin production to protection across tissues.S1S7
Where the reasoning is carried by something unstated · 2
- Master question. The search assumes that a shared causal target can be altered in a way that benefits several systems. The goal supplies this possibility, not evidence that such a target exists.
- Goal pillar. The narrowing assumes that persistence of a damaged state is a useful shared target. The master question does not specifically establish that choice.
How a result here could mislead · 3
- Loss of benefit after disabling platelet 12-lipoxygenase could reflect altered clotting rather than loss of the proposed protective chemical production. What closes it: The specification calls for separate assessment of platelet function. Interpretation also requires verified enzyme shutdown, measurement of the intended chemical products, and assessment of whether supplying the corresponding product restores function without merely correcting a clotting disturbance.
- More lipoxins alongside improved function could be mistaken for proof that lipoxins caused the improvement. Protection could instead come from clearing harmful cell-released particles, suppressing immune damage through other particles, or making neighboring cells more resistant to injury. What closes it: The proposed tracing with an isotopically labeled precursor, a starting molecule marked with a distinguishable form of an atom, must establish its contribution to lipoxin production. The specified checks on competing protective routes must accompany enzyme shutdown and product replacement; uptake of harmful cell-released particles also needs measurement because the design does not explicitly hold that rival route constant.
- Early improvement in one tissue could be read as shared recovery while retained neutrophils move elsewhere and cause later injury. What closes it: Muscle, heart, and lung outcomes must be evaluated separately over a predefined follow-up period, alongside neutrophil location. The supplied specification gives no duration or criterion sufficient to exclude delayed redistribution of damage.
What would make this wrong. The proposed mechanism would be contradicted if EP2 suppression retained its benefit despite confirmed shutdown of platelet 12-lipoxygenase and verified interruption of the proposed lipoxin-production route, with neutrophil retention and platelet function adequately accounted for. The hypothesis explicitly makes dependence on that platelet enzyme a required prediction.
What it would change. If the hypothesis held, a candidate shared target for healthier aging would be the continued production of protective chemicals by cooperating cells. Removing whole neutrophils would not be necessary for benefit under the tested conditions, and their remaining chemical activity would become essential to interpreting recovery. That would not rule out a causal role for removing harmful cell products, establish longer life, or establish effectiveness in humans; the proposed test does not specify its species, duration, or a lifespan outcome.
Sources read · 9
Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. · The Journal of clinical investigation · 1990
“In cell-free 100,000 g supernatants of platelet lysates, which displayed 12-LO activity, LTA4 was also transformed to lipoxins.”
Does not settle: Источник показывает этот ферментативный этап только in vitro в человеческих нейтрофилах и тромбоцитах. Он не устанавливает влияние подавления EP2, изменения резидентных макрофагов, блокады поглощения нейтрофилов, восстановление межклеточного потока, SPV_3 или ограничение повреждения тканей.
Platelets may inhibit leucotriene biosynthesis by human neutrophils at the integrin level. · British journal of haematology · 2003
“The production of transcellular metabolites of AA such as LTC4, the dual 5- and 12-lipoxygenase product 5,12-diHETE and lipoxins could not account for the decreased formation of 5-HETE and LTA4-derived metabolites.”
Does not settle: Источник не устанавливает влияние подавления EP2, фагоцитоза нейтрофилов, резидентных макрофагов, SPV_3, повреждения тканей или восстановления межклеточного синтеза.
Trout thrombocytes contain 12- but not 5-lipoxygenase activity. · Biochimica et biophysica acta · 1999
“MACS +ve cells (thrombocytes) generated no 4 or 5 series LT or LX but did generate significant amounts of the 12-lipoxygenase (LO) products, 12-HETE and 12-HEPE.”
Does not settle: Источник исследует тромбоциты радужной форели in vitro. Он не устанавливает эффекты подавления EP2, среду резидентных макрофагов, сохранение нейтрофилов, межклеточный синтез липоксинов у млекопитающих или человека, повреждение тканей либо SPV_3.
Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling. · The Journal of experimental medicine · 2009
“Moreover, intrapulmonary administration of ACs demonstrated that PGE 2 generated during efferocytosis and acting via EP2 accounts for subsequent impairment of lung recruitment of polymorphonuclear leukocytes and clearance of Streptococcus pneumoniae , as well as enhanced generation of IL-10 in vivo.”
Does not settle: Источник описывает PGE2/EP2-сигналинг при эффероцитозе в лёгких. Он не исследует ингибирование EP2, 12-липоксигеназу тромбоцитов, липоксины, межклеточный синтез липидов, сохранение нейтрофилов при блокаде их поглощения, SPV_3 или повреждение нескольких тканей.
Efferocytosis-induced prostaglandin E2 production impairs alveolar macrophage effector functions during Streptococcus pneumoniae infection. · Innate immunity · 2017
“Efferocytosis slightly decreased the phagocytosis of S. pneumoniae but greatly inhibited bacterial killing by AMs in a manner dependent on PGE2 production, activation of the EP2-EP4/cAMP/PKA pathway and inhibition of H2O2 production.”
Does not settle: Источник описывает резидентные альвеолярные макрофаги в условиях эксперимента с апоптотическими клетками Jurkat и S. pneumoniae. Он не устанавливает влияние подавления EP2 на нейтрофилы, тромбоциты, 12-липоксигеназу, липоксины, межклеточный синтез липидов, SPV_3 или повреждение нескольких тканей.
Signaling via macrophage G2A enhances efferocytosis of dying neutrophils by augmentation of Rac activity. · The Journal of biological chemistry · 2011
“Subsequent signaling by PGE 2 via EP2 receptors activated macrophage adenylyl cyclase and protein kinase A. These events, in turn, culminated in enhanced activity of Rac1, resulting in an increase in both the numbers of macrophages efferocytosing apoptotic cells and the numbers of cells ingested per macrophage.”
Does not settle: Источник не исследует подавление EP2, резидентные макрофаги, тромбоцитарную 12-липоксигеназу, липоксины, межклеточный синтез липидов, SPV_3 или повреждение нескольких тканей.
Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging. · Science (New York, N.Y.) · 2026
“Reducing TRM EP2 signaling in aged mice preserved youthful mitochondrial fitness and prevented cognitive decline, frailty, sarcopenia, adiposity, cardiac impairment, and systemic inflammation.”
Does not settle: В абстракте не рассматриваются нейтрофильно-тромбоцитарный совместный синтез липидов, тромбоцитарная 12-липоксигеназа, липоксины, химический поток между клетками, SPV_3 или блокада поглощения нейтрофилов. Он также не устанавливает, что восстановление такого пути ограничивает новое повреждение нескольких тканей.
Consequences of transcellular biosynthesis of leukotriene C4 on organ function. · Haemostasis · 1996
“Transcellular biosynthesis of leukotriene C4 occurs via transfer of the reactive intermediate leukotriene A4 from neutrophils to vicinal acceptor cells devoid of 5-lipoxygenase activity such as platelets or vascular cells.”
Does not settle: Источник не изучает подавление EP2, резидентные макрофаги, тромбоцитарную 12-липоксигеназу, образование липоксинов, блокаду поглощения нейтрофилов, SPV_3 или повреждение нескольких тканей.
Transcellular biosynthesis of sulfidopeptide leukotrienes during receptor-mediated stimulation of human neutrophil/platelet mixtures. · Blood · 1990
“In the presence of stimulated neutrophils, the final synthesis of LTC4 was shown to occur within the platelets (from neutrophil-derived LTA4)”
Does not settle: The source does not establish platelet 12-lipoxygenase conversion of a neutrophil intermediate into lipoxins, EP2 inhibition, resident macrophage changes, blockade of neutrophil engulfment, SPV_3, tissue damage outcomes, or effects across multiple tissues.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Does suppressing a cell signal still benefit several body systems when improved removal of worn-out immune cells is blocked?
Original wording · exactly as the pipeline generated it
Сохранится ли многосистемная польза подавления EP2, если избирательно воспрепятствовать восстановлению удаления нейтрофилов, и опровергнет ли такой результат очистку как общее причинное звено?
What this question is asking
The question asks whether improved removal of worn-out neutrophils, a type of immune cell, is necessary for benefits across several body systems. The intervention suppresses signaling through E prostanoid receptor subtype 2 (EP2) in tissue-resident macrophages, immune cells that live in tissues and remove cellular material. The comparison is between suppression that allows neutrophil removal to improve and the same suppression with that improvement selectively prevented. The question assumes that suppression improves both removal and several aspects of health in aged mice, while treating removal as a possible shared cause of those benefits. It also asks whether benefits persisting when improved removal is blocked would disprove that proposed causal explanation.
- E prostanoid receptor subtype 2 (EP2)
- A cell receptor through which prostaglandin E2 sends signals. The question concerns reducing its signaling in tissue-resident macrophages; the supplied sources report different consequences of this signaling in different settings.
- Prostaglandin E2
- A signaling molecule that acts through receptors including EP2. In the supplied sources, its signaling is linked to increased removal of dying cells, impaired bacterial killing, and protection against scarring, so its effects cannot be reduced to a single beneficial or harmful role.
- Neutrophils
- A type of immune cell. The question concerns removal of worn-out neutrophils, rather than their production or every function they perform.
- Senescent neutrophils
- The aged or worn-out neutrophils named in S1's title. The supplied material does not specify how that state was identified or whether it matches the dying-cell states studied in the other sources.
- Tissue-resident macrophages
- Immune cells that reside in tissues and can ingest cells and other material. They are the cells whose EP2 signaling was reduced in S1.
- Clearance
- Removal of cells or other material from a tissue. Here, the proposed causal step is improved removal of neutrophils; reduced accumulation alone would not specify how that reduction occurred.
- Programmed cell death
- An organized process through which cells die. The dying cells ingested in S6 should not automatically be treated as equivalent to every neutrophil described as senescent in S1.
- Mitochondrial fitness
- The functional condition of mitochondria, structures within cells involved in supplying usable energy. S1 reports preservation of this condition but the supplied quotation does not specify its measurement.
- Inflammation
- A tissue and immune response to injury or threats. Body-wide inflammation is one of S1's reported outcomes, while the question asks whether improved cell removal explains its reduction.
- Cognitive decline and frailty
- Cognitive decline means worsening abilities such as memory and thinking; frailty means increased vulnerability associated with reduced physical reserves. Both are outcomes named in S1, but their measurement criteria are not supplied.
- Hydrogen peroxide
- A reactive chemical involved in the bacterial-killing mechanism described in S5. That source links reduced production of it to impaired bacterial killing.
- Scarring
- Formation of fibrous tissue, also called fibrosis. S8 concerns a possible loss of protection against this process in the uterine lining.
- Selective prevention
- The question's assumed ability to stop improvement in neutrophil removal while keeping EP2 suppression effective and avoiding other changes that could explain the outcomes. The supplied sources do not establish that this separation was achieved.
- Necessary and sufficient causes
- A necessary step must occur for a particular benefit to occur under the stated conditions. A sufficient step can produce that benefit on its own; showing necessity does not establish sufficiency.
Suppressing EP2 improves neutrophil clearance and macrophage condition in aged mice and produces benefits across several body systems, with clearance proposed as their common causal link.
Neutrophils are immune cells, and tissue-resident macrophages are cells that can remove them as they become worn out. The assumption is that reducing signaling through a receptor on these macrophages improves their condition and removal work, alongside benefits elsewhere in the body. If established, that connection would provide the starting point for asking whether improved removal is required for those benefits.
S1 directly reports that reducing macrophage EP2 signaling in aged mice preserved mitochondrial fitness and prevented several adverse outcomes. Its title identifies restored clearance of senescent neutrophils as the subject, but the supplied abstract quotation does not detail that clearance result or establish its necessity for the broader benefits. S6 reports increased uptake of dying cells following EP2 activation in another setting, so a general claim that less EP2 signaling necessarily improves clearance is not supported. None of the supplied passages establishes clearance as the necessary common cause.S1S6
The same question asked without the part nothing read establishes:
- In aged mice, do the benefits of reducing EP2 signaling persist when improved neutrophil removal is selectively prevented?
- Which benefits of reducing EP2 signaling in aged mice require improved neutrophil removal?
- Benefits persist across systems If improved neutrophil removal were genuinely prevented while receptor suppression remained effective, persistent benefits would mean that this improvement was not necessary for those measured benefits under those conditions. That would challenge clearance restoration as their required common cause, while leaving possible contributions from existing clearance or other settings unresolved.
- Benefits disappear across systems Under the question's assumption of selective interference, losing the benefits would support a requirement for improved neutrophil removal. It would not by itself establish that removal is the sole cause or that improving removal alone is sufficient to produce those benefits.
- Some benefits persist and others disappear Under the same selectivity assumption, the outcomes would differ in their dependence on improved neutrophil removal. Clearance restoration could then explain some benefits without serving as a necessary common link for every measured system.
The proposed chain runs from reduced receptor signaling to improved removal of worn-out immune cells, then to less inflammation and better function across several body systems. If improved removal is necessary, blocking that improvement would interrupt the chain despite continued receptor suppression. If benefits persist, the proposed explanation would need to distinguish benefits that require improved removal from benefits that do not. Mistaking an accompanying change for a necessary cause would misidentify why the intervention works; assuming that receptor suppression always helps would also overlook the opposing effects reported in other biological settings.
Подавление EP2 улучшает очистку и состояние макрофагов у мышей, RL-1; необходимость очистки для общего устойчивого эффекта отдельно не установлена.
Воспаление и функции возвращаются в заданные диапазоны за дни или недели; повторные нагрузки сохраняют восстановление нескольких систем месяцами.
Требуется разорвать предполагаемую причинную цепь и проверить, исчезает ли многосистемная польза при сохранённом воздействии на EP2.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Подавление EP2 предположительно меняет среду резидентных макрофагов и соотношение продуктов совместного ферментативного синтеза в нейтрофилах и тромбоцитах. Промежуточный продукт нейтрофила перерабатывается тромбоцитарной 12-липоксигеназой в липоксины, способствующие завершению воспаления. Сохранившиеся нейтрофилы продолжают участвовать в этом синтезе при блокаде их поглощения. Общий эффект определяется химическим потоком через межклеточную последовательность ферментативных реакций. Его восстановление должно сокращать SPV_3 и ограничивать новое повреждение нескольких тканей.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
Польза подавления EP2 сохраняется при блокаде поглощения нейтрофилов и сопровождается усилением образования липоксинов из изотопно меченного нейтрофильного предшественника. Тромбоцит-специфическое выключение 12-липоксигеназы устраняет этот эффект при сохранённых количестве нейтрофилов, активности CD55 на везикулах и потоке итаконата. Введение соответствующего продукта синтеза восстанавливает функции. Отсутствие зависимости от тромбоцитарного фермента при подтверждённом его выключении опровергает гипотезу.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies observable persistence, increased lipoxin formation, loss of the effect under controlled conditions, functional rescue, and an explicit rejection condition. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Совместный синтез липоксинов нейтрофилами и тромбоцитами изучался на человеческих клетках. Проверка требует раздельного мечения клеточных источников и количественного анализа липидов с подлинными стандартами. Изменение функции тромбоцитов контролируют отдельно, чтобы отделить биосинтез от нарушений гемостаза.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
Польза подавления EP2 сохраняется при блокаде поглощения нейтрофилов и сопровождается усилением образования липоксинов из изотопно меченного нейтрофильного предшественника. Тромбоцит-специфическое выключение 12-липоксигеназы устраняет этот эффект при сохранённых количестве нейтрофилов, активности CD55 на везикулах и потоке итаконата. Введение соответствующего продукта синтеза восстанавливает функции. Отсутствие зависимости от тромбоцитарного фермента при подтверждённом его выключении опровергает гипотезу.
- What would separate them
Delaying neutrophil uptake may preserve vesicle-mediated complement inhibition predicts: При подтверждённом подавлении EP2 и одинаковом исходном повреждении блокада поглощения нейтрофилов дополнительно улучшает восстановление мышцы, сердца и лёгких. Этот дополнительный выигрыш исчезает при нейтрофил-специфическом выключении CD55 и возвращается после введения очищенных CD55-положительных везикул. Напротив, независимое ускорение удаления нейтрофилов при сохранённой блокаде EP2 ухудшает восстановление, если происходит до образования защитных везикул. Простое сохранение пользы при блокаде поглощения для подтверждения этой гипотезы недостаточно.
- What would separate them
Vesicle removal may limit damage from elastase shielded against its natural inhibitor predicts: При блокаде поглощения целых нейтрофилов эффект подавления EP2 сохраняется только при снижении количества везикул с активной эластазой. Возврат очищенной фракции таких везикул устраняет пользу; равное количество везикул с инактивированной эластазой этого не делает. При одинаковой активности против свободной эластазы малый ингибитор подавляет везикулярную протеазу и восстанавливает функции эффективнее крупного ингибитора. После отделения эластазы от поверхности размерная зависимость исчезает.
- What would separate them
Suppressing a prostaglandin receptor may curb ferroptosis through itaconate predicts: При подавлении EP2 и блокаде поглощения нейтрофилов функции улучшаются на фоне сопоставимых количества нейтрофилов, активности комплемента и внеклеточной эластазы. Одновременно снижаются окисленные фосфолипиды и гибель паренхиматозных клеток. Макрофаг-специфическое выключение фермента синтеза итаконата ACOD1 устраняет этот выигрыш; прямое подавление ферроптоза в клетках-мишенях восстанавливает его при продолжающейся блокаде поглощения. Отсутствие увеличения потока природного итаконата после подавления EP2 опровергает предложенную связь.
- What would separate them
Neutrophil movement may shift damage between organs and mimic lasting recovery predicts: После подавления EP2 на фоне блокады поглощения меченые нейтрофилы исчезают из исходной ткани, но сохраняются в крови и обнаруживаются в удалённых органах. Раннее улучшение мышцы сопровождается отсроченным ухудшением лёгочной или сердечной функции после повторной обычной нагрузки. За заранее заданный период наблюдения согласованного функционального выигрыша трёх систем нет. Подтверждённое улучшение всех трёх систем на протяжении месяцев при отсутствии переноса клеточной нагрузки опровергает эту гипотезу.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.